X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
transplantation (20) 20
hematology (19) 19
oncology (16) 16
humans (15) 15
male (13) 13
female (12) 12
aged (11) 11
middle aged (11) 11
adult (10) 10
chemotherapy (10) 10
hematology, oncology and palliative medicine (9) 9
article (8) 8
immunology (8) 8
leukemia (8) 8
stem cells (8) 8
treatment outcome (7) 7
aml (5) 5
care and treatment (5) 5
lymphocytes (5) 5
lymphomas (5) 5
multiple myeloma (5) 5
risk factors (5) 5
adults (4) 4
aged, 80 and over (4) 4
analysis (4) 4
animals (4) 4
bone marrow (4) 4
bortezomib (4) 4
cancer (4) 4
chimeric antigen receptor (4) 4
cytokines (4) 4
fludarabine (4) 4
hematopoietic stem cell transplantation - methods (4) 4
hematopoietic stem cells (4) 4
lymphocytes t (4) 4
lymphoma (4) 4
medicine, research & experimental (4) 4
mortality (4) 4
outcomes (4) 4
remissions (4) 4
t-lymphocytes - immunology (4) 4
therapy (4) 4
abridged index medicus (3) 3
adolescent (3) 3
antigens (3) 3
azacitidine - administration & dosage (3) 3
b-cell lymphoma (3) 3
car t cell therapy (3) 3
cd19 antigen (3) 3
cyclophosphamide (3) 3
expression (3) 3
health aspects (3) 3
hemic and lymphatic diseases (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - therapy (3) 3
lymphocytes b (3) 3
malignancies (3) 3
mice (3) 3
myelodysplastic syndromes - drug therapy (3) 3
neutropenia (3) 3
older patients (3) 3
patients (3) 3
recurrence (3) 3
salvage therapy - methods (3) 3
survival (3) 3
t-lymphocytes - metabolism (3) 3
time factors (3) 3
transplantation, homologous - methods (3) 3
versus-host-disease (3) 3
young adult (3) 3
5-aza-2'-deoxycytidine (2) 2
acute lymphocytic leukemia (2) 2
acute myelogenous leukemia (2) 2
acute myeloid leukemia (2) 2
anemia (2) 2
antigens, cd34 - metabolism (2) 2
antimetabolites, antineoplastic - administration & dosage (2) 2
antimetabolites, antineoplastic - adverse effects (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
azacitidine (2) 2
azacitidine - adverse effects (2) 2
azacitidine - analogs & derivatives (2) 2
b-cell (2) 2
bacteremia (2) 2
biomarkers (2) 2
biotechnology & applied microbiology (2) 2
blinatumomab (2) 2
blood (2) 2
blood diseases (2) 2
bone-marrow-transplantation (2) 2
boost infusion (2) 2
car t (2) 2
cardiac arrhythmia (2) 2
cell therapy (2) 2
cohort studies (2) 2
complications and side effects (2) 2
cytarabine consolidation (2) 2
cytokine release syndrome (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2531 - 2544
Journal Article
Molecular Therapy, ISSN 1525-0016, 01/2017, Volume 25, Issue 1, pp. 285 - 295
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an... 
refractory NHL | diffuse large B cell lymphoma | CAR T | CD19 | KTE-C19 | MEDICINE, RESEARCH & EXPERIMENTAL | CD8(+) | MANAGEMENT | SUBSETS | CHEMOTHERAPY | TRANSPLANTATION | MALIGNANCY | B-CELL | REMISSIONS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | BLINATUMOMAB | OUTCOMES | Lymphoma, Non-Hodgkin - immunology | Follow-Up Studies | Humans | Middle Aged | Receptor-CD3 Complex, Antigen, T-Cell - genetics | Drug Resistance, Neoplasm | Male | Recombinant Fusion Proteins | CD28 Antigens - metabolism | Receptor-CD3 Complex, Antigen, T-Cell - metabolism | Lymphoma, Large B-Cell, Diffuse - therapy | CD28 Antigens - genetics | T-Lymphocytes - metabolism | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Antigens, CD19 - immunology | Immunotherapy, Adoptive - adverse effects | Immunotherapy, Adoptive - methods | Immunophenotyping | Treatment Outcome | Combined Modality Therapy | Disease Progression | Lymphoma, Large B-Cell, Diffuse - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Biomarkers | T-Lymphocytes - immunology | Aged | Neoplasm Staging | Lymphoma, Non-Hodgkin - diagnosis | Delirium | Cardiac arrhythmia | CD19 antigen | Kidneys | Cytokines | Lymphocytes T | Metabolism | CD28 antigen | Patients | Lymphoma | Neurotoxicity | Cyclophosphamide | Chemotherapy | Fludarabine | Lymphocytes B | Lymphocytes | Response rates | Sepsis | Hypoxia | Lymphomas | Neutropenia | B-cell lymphoma | Index Medicus | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2023 - 2036
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 31 - 42
Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study,... 
2-YEAR SURVIVORS | HODGKIN | CHIMERIC ANTIGEN RECEPTOR | OUTCOMES | ONCOLOGY | TRANSPLANTATION | Analysis | Lymphomas | Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S382 - S383
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S404 - S404
Autologous stem cell transplantation (ASCT) is used sparingly among myeloma (MM) patients with renal impairment due to concerns of morbidity and mortality. A... 
Kidney failure | Patient outcomes | Analysis | Mortality | Multiple myeloma | Stem cells | Transplantation | Information management
Journal Article
Leukemia Research, ISSN 0145-2126, 2016, Volume 49, pp. 1 - 6
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2017, Volume 23, Issue 7, pp. 1072 - 1077
Highlights • CD34+ -selected stem cell boost is an effective treatment for poor graft function. • The addition of plerixafor increases CD34+ yield over G-CSF... 
Hematology, Oncology and Palliative Medicine | boost infusion | stem cell boost | Poor graft functions | cell therapy
Journal Article
Case reports in hematology, ISSN 2090-6560, 2017, Volume 2017, pp. 3728429 - 3
Posttransplant Lymphoproliferative Disorder (PTLD) is one of the most common malignancies complicating solid organ transplantation. In contrast, PTLD accounts... 
Complications and side effects | Development and progression | Care and treatment | Transplantation | Hematopoietic stem cells | Multiple myeloma | Proteins | Plasma | Transplants & implants | Anemia | Pathogenesis | Leukemia | Stem cells | Bone marrow | Lymphomas | Risk factors | Case Report
Journal Article
LEUKEMIA, ISSN 0887-6924, 09/2018, Volume 32, Issue 9, pp. 1970 - 1983
Journal Article
Molecular Therapy, ISSN 1525-0016, 06/2015, Volume 23, Issue 6, pp. 1110 - 1122
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3776 - 3783
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM).... 
LENALIDOMIDE | FAMILY PROTEINS | BORTEZOMIB | ONCOLOGY
Journal Article